

Table 2 - continued Incidence of clinical signs
Female

Sex	Group and dose	Clinical sign	Days																					
			220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9
		Abnormality of tooth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Mass	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	2.5 mg/kg	Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	12.5 mg/kg	No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Loss of hair		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Soiled perinaris		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Torticollis		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Bradypnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Lateral position		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Dyspnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Imminently sacrifice		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 2 - continued Incidence of clinical signs
Female

Sex	Group and dose	Clinical sign	Days																					
			242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	9	9	9	9	9	9	9	9	9	9	9	8	8	8	8	8	8	8	8	8	8	8
		Abnormality of tooth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Mass	1	1	1	1	1	1	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2	
	0.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	12.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Loss of hair		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Soiled perinaris		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Torticollis		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Bradypnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Lateral position		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Dyspnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Imminently sacrifice		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 2 - continued Incidence of clinical signs
Female

Sex	Group and dose	Clinical sign	Days																					
			264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	8	8	8	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
		Abnormality of tooth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Corn	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Mass	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
	0.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	12.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
No abnormality		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
Corn		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Mass		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Loss of hair		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Soiled perianis		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Torticollis		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Bradypnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Lateral position		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Dyspnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Imminently sacrifice		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 2 - continued Incidence of clinical signs
Female

Sex	Group and dose	Clinical sign	Days																					
			286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
		Abnormality of tooth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Corn	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Mass	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
	0.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	12.5 mg/kg	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Loss of hair	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Soiled perinarius		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Torticollis		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Bradypnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Lateral position		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Dyspnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Imminently sacrifice		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 2 - continued Incidence of clinical signs
Female

Sex	Group and dose	Clinical sign	Days																						
			308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
		Abnormality of tooth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Corn	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		Mass	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	0.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	2.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	12.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Mass		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Loss of hair		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Soiled perianaris		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Torticollis		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Bradypnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Lateral position		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Dyspnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Imminently sacrifice	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			

Table 2 - continued Incidence of clinical signs
Female

Sex	Group and dose	Clinical sign	Days																						
			330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
		Abnormality of tooth	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Corn	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Mass	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
	0.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	9	9	9	9	9	9	9	9
	2.5 mg/kg	Corn	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		Mass	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	10	10	10	10	9	9	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	
	12.5 mg/kg	Corn	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
Mass		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1		
Loss of hair		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1		
Soiled perinearis		0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1		
Torticollis		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1		
Bradypnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1		
Lateral position		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Dyspnea		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Imminently sacrifice		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		

Table 2 - continued

Incidence of clinical signs
Female

Sex	Group and dose	Clinical sign	Days												
			352	353	354	355	356	357	358	359	360	361	362	363	364
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	7	7	7	7	7	7	7	7	7	7	7	7	7
		Abnormality of tooth	0	0	0	0	0	0	0	0	0	0	0	0	0
		Corn	1	1	1	1	1	1	1	1	1	1	1	1	1
	Mass	2	2	2	2	2	2	2	2	2	2	2	2	2	
	0.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	9	9	9	9	9	9	9	9	9	9	9	9	10
		Corn	1	1	1	1	1	1	1	1	1	1	1	1	0
	2.5 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	8	8	8	8	8	8	8	8	8	8	8	8	7
		Corn	1	1	1	2	1	1	1	1	1	1	1	1	2
		Mass	1	1	1	1	1	1	1	1	1	1	1	1	1
	12.5 mg/kg	Number of examined	10	10	10	9	9	9	9	9	9	9	9	9	9
		No abnormality	7	7	7	7	7	7	7	6	6	6	6	6	5
		Corn	1	1	1	1	1	1	1	1	1	1	1	1	2
Mass		1	1	1	1	1	1	1	2	2	2	2	2	3	
Loss of hair		0	0	0	0	0	0	0	0	0	0	0	0	0	
Hypoactivity		1	1	0	0	0	0	0	0	0	0	0	0	0	
Soiled perinaris		1	1	1	0	0	0	0	0	0	0	0	0	0	
Torticollis		1	1	1	0	0	0	0	0	0	0	0	0	0	
Bradypnea		1	1	0	0	0	0	0	0	0	0	0	0	0	
Lateral position		0	0	1	0	0	0	0	0	0	0	0	0	0	
Dyspnea		0	0	1	0	0	0	0	0	0	0	0	0	0	
Imminently sacrifice	0	0	1	0	0	0	0	0	0	0	0	0	0		

Table 3 Body weights
Male, Female

Sex	Group and dose		Body weight(g) on day										
			1	8	15	22	29	36	43	50	57	64	
Male	Control	N	20	20	20	20	20	20	20	20	20	20	20
		Mean	212.1	267.5	320.9	362.2	400.2	431.3	456.1	479.2	501.7	520.9	
		S.D.	±8.5	±14.3	±23.7	±30.2	±36.7	±40.0	±42.3	±44.9	±50.0	±52.9	
	0.1 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20
		Mean	212.4	271.5	327.0	372.7	414.5	445.6	469.9	495.1	521.6	537.6	
		S.D.	±9.1	±13.6	±19.0	±24.8	±27.5	±29.6	±31.0	±33.4	±34.5	±37.3	
	0.5 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20
		Mean	211.5	274.5	334.9	381.2	423.2	456.6	481.6	505.5	526.6	545.0	
		S.D.	±9.5	±14.6	±20.3	±25.3	±30.6	±33.6	±36.0	±38.4	±40.5	±44.1	
	2.5 mg/kg	N	20	20	20	20	20	20	20	20	19	19	
		Mean	212.0	268.5	317.5	353.9	382.1	404.4*	421.1**	438.8**	454.4**	466.2**	
		S.D.	±10.1	±13.3	±18.7	±23.1	±25.9	±29.6	±32.2	±38.8	±42.3	±46.6	
Female	Control	N	20	20	20	20	20	20	20	20	20	20	
		Mean	157.7	187.3	210.8	235.1	249.1	261.3	268.6	276.1	286.1	290.9	
		S.D.	±8.6	±11.1	±12.6	±15.7	±16.5	±17.3	±18.1	±17.7	±21.4	±22.8	
	0.5 mg/kg	N	20	20	20	20	20	20	20	20	20	20	
		Mean	159.1	187.9	212.3	237.2	250.9	261.9	270.2	281.2	289.5	294.3	
		S.D.	±8.3	±11.6	±13.4	±18.0	±19.3	±21.3	±21.6	±23.7	±25.5	±27.0	
	2.5 mg/kg	N	20	20	20	20	20	20	20	20	20	20	
		Mean	159.0	190.0	211.9	238.4	253.4	265.7	273.3	284.9	293.5	298.6	
		S.D.	±7.9	±10.9	±13.1	±15.7	±17.4	±18.9	±19.8	±21.8	±23.6	±24.6	
	12.5 mg/kg	N	20	20	20	20	20	20	20	20	20	20	
		Mean	157.1	189.1	213.8	238.3	252.7	265.5	272.6	281.5	290.2	295.1	
		S.D.	±8.4	±11.8	±13.4	±15.9	±18.3	±19.3	±18.3	±21.1	±22.5	±23.2	

*: P<0.05, **: P<0.01 (significantly different from control).

Table 3 - continued
Body weights
Male, Female

Sex	Group and dose		Body weight (g) on day									
			71	78	85	91	92	120	148	176	204	232
Male	Control	N	20	20	20	20	10	10	10	10	10	10
		Mean	531.7	546.4	558.8	568.3	583.0	625.2	657.5	683.9	713.3	735.3
		S.D.	±54.6	±55.4	±59.0	±60.7	±79.8	±88.8	±102.5	±111.5	±118.1	±113.7
	0.1 mg/kg	N	20	20	20	20	10	10	10	10	10	9
		Mean	553.0	569.9	583.3	589.4	590.4	616.0	643.8	668.9	693.1	730.0
		S.D.	±35.9	±38.5	±40.1	±40.0	±39.5	±64.6	±69.7	±74.8	±76.4	±74.4
	0.5 mg/kg	N	20	20	20	20	10	10	10	10	10	10
		Mean	560.3	575.9	586.4	594.3	617.0	648.9	685.1	706.5	736.8	759.3
		S.D.	±47.1	±48.6	±49.8	±52.4	±52.7	±61.7	±71.0	±82.7	±90.7	±98.4
	2.5 mg/kg	N	19	19	19	19	10	10	10	10	10	10
		Mean	475.4**	483.8**	491.5**	493.2**	515.0*	535.9*	554.5*	565.4*	588.7*	593.7**
		S.D.	±46.4	±49.4	±50.8	±51.8	±61.0	±59.2	±65.0	±68.2	±74.8	±82.7
Female	Control	N	20	20	20	20	10	10	10	10	10	
		Mean	296.2	302.5	309.1	315.2	308.3	321.7	334.9	348.6	359.3	375.7
		S.D.	±22.5	±24.6	±25.7	±26.8	±26.9	±29.4	±35.8	±41.2	±47.1	±56.3
	0.5 mg/kg	N	20	20	20	20	10	10	10	10	10	10
		Mean	299.0	307.4	312.2	314.0	309.7	325.2	341.8	354.4	365.1	380.6
		S.D.	±27.1	±28.5	±29.7	±30.6	±28.5	±36.2	±36.1	±41.0	±42.4	±46.3
	2.5 mg/kg	N	20	20	20	20	10	10	10	10	10	10
		Mean	301.9	311.4	316.8	320.4	328.9	350.7	362.8	376.5	391.4	411.8
		S.D.	±26.0	±28.0	±30.3	±31.7	±39.3	±46.0	±49.2	±54.3	±60.6	±70.8
	12.5 mg/kg	N	20	20	20	20	10	10	10	10	10	10
		Mean	300.3	306.0	309.1	311.9	307.5	324.0	337.7	348.3	361.7	373.7
		S.D.	±23.6	±24.8	±27.4	±24.6	±28.0	±31.8	±31.2	±35.4	±36.1	±37.1

*: P<0.05, **: P<0.01 (significantly different from control).

Table 3:- continued
Body weights
Male, Female

Sex	Group and dose		Body weight(g) on day				
			260	288	316	344	364
Male	Control	N	10	10	10	10	10
		Mean	756.3	786.6	807.1	832.0	843.4
		S.D.	±117.4	±131.2	±136.9	±145.8	±152.9
	0.1 mg/kg	N	9	9	9	9	8
		Mean	748.2	768.4	786.2	795.8	811.9
		S.D.	±90.8	±101.6	±114.1	±129.1	±144.5
	0.5 mg/kg	N	10	10	10	10	10
		Mean	790.8	813.2	832.0	858.3	862.3
		S.D.	±112.4	±118.0	±124.8	±136.1	±139.3
	2.5 mg/kg	N	10	10	10	10	10
		Mean	609.5**	620.7**	623.8**	643.3**	639.4**
		S.D.	±84.2	±88.2	±85.5	±97.1	±96.7
Female	Control	N	10	10	10	10	10
		Mean	394.5	404.6	417.1	430.5	440.1
		S.D.	±66.0	±71.8	±79.9	±85.6	±87.7
	0.5 mg/kg	N	10	10	10	10	10
		Mean	396.2	414.7	433.8	448.5	457.9
		S.D.	±53.5	±57.5	±63.3	±70.3	±73.4
	2.5 mg/kg	N	10	10	10	10	10
		Mean	432.8	446.8	471.1	484.6	495.0
		S.D.	±77.2	±83.2	±98.0	±99.8	±105.5
	12.5 mg/kg	N	10	10	10	10	9
		Mean	390.3	402.3	416.8	426.2	442.4
		S.D.	±41.4	±48.9	±54.3	±69.0	±72.2

** : P<0.01 (significantly different from control).

Table 4 Food consumption
Male, Female

Sex	Group and dose		Food consumption (g) on day										
			2	8	15	22	29	36	43	50	57	64	
Male	Control	N	20	20	20	20	20	20	20	20	20	20	20
		Mean	23.1	23.7	24.6	23.3	23.1	23.1	23.4	22.8	22.6	21.5	
		S.D.	±2.1	±2.2	±2.9	±3.1	±3.1	±2.3	±2.6	±2.4	±3.2	±3.6	
	0.1 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20
		Mean	22.7	25.3	24.4	24.5	23.4	22.7	22.5	23.2	22.5	21.1	
		S.D.	±1.8	±2.4	±2.6	±2.6	±2.4	±2.3	±2.6	±2.7	±2.1	±2.6	
	0.5 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20
		Mean	23.5	25.8*	25.8	23.6	24.3	24.2	24.3	24.3	24.2	23.7*	
		S.D.	±1.9	±2.1	±2.8	±2.5	±2.1	±1.8	±1.9	±2.4	±2.2	±2.2	
	2.5 mg/kg	N	20	20	20	20	20	20	20	20	19	19	
		Mean	23.0	23.7	23.2	22.4	21.7	23.0	21.4	22.5	22.5	21.7	
		S.D.	±2.3	±2.1	±3.1	±2.9	±2.8	±3.1	±3.6	±3.8	±3.7	±3.0	
Female	Control	N	20	20	20	20	20	20	20	20	20	20	
		Mean	16.5	16.5	16.3	15.9	15.9	16.1	15.7	14.2	15.0	13.4	
		S.D.	±2.3	±2.8	±2.1	±2.0	±3.0	±3.2	±2.6	±2.4	±2.2	±2.6	
	0.5 mg/kg	N	20	20	20	20	20	20	20	20	20	20	
		Mean	16.6	16.3	15.5	15.2	15.2	15.4	15.0	15.2	14.9	12.6	
		S.D.	±1.7	±2.8	±2.2	±1.5	±1.9	±3.1	±2.5	±2.4	±2.4	±2.6	
	2.5 mg/kg	N	20	20	20	20	20	20	20	20	20	20	
		Mean	16.4	16.7	15.5	15.4	16.1	16.2	14.8	16.0	14.6	12.9	
		S.D.	±1.7	±1.8	±2.3	±1.9	±1.9	±2.0	±3.2	±2.2	±1.8	±2.4	
	12.5 mg/kg	N	20	20	20	20	20	20	20	20	20	20	
		Mean	16.5	17.1	16.3	15.4	15.8	16.0	14.8	16.0	14.9	14.2	
		S.D.	±1.8	±2.1	±2.2	±2.4	±2.9	±2.6	±1.8	±2.7	±2.3	±3.0	

*: P<0.05 (significantly different from control).

Table 4 - continued Food consumption
Male, Female

Sex	Group and dose		Food consumption(g) on day										
			71	78	85	91	92	120	148	176	204	232	
Male	Control	N	20	20	20	20	10	10	10	10	10	10	
		Mean	20.0	21.0	20.9	20.7	20.9	20.8	20.7	21.7	20.1	16.5	
		S.D.	±2.6	±3.2	±4.0	±3.1	±3.9	±3.4	±4.3	±4.0	±3.0	±2.1	
	0.1 mg/kg	N	20	20	20	20	10	10	10	10	10	9	
		Mean	19.4	21.5	20.6	19.9	19.6	19.1	20.6	19.8	18.9	17.3	
		S.D.	±2.7	±2.4	±2.3	±2.9	±3.2	±4.6	±3.0	±2.2	±3.4	±2.3	
	0.5 mg/kg	N	20	20	20	20	10	10	10	10	10	10	
		Mean	22.5*	23.8**	22.1	22.2	21.1	22.0	23.7	23.0	22.9	19.4*	
		S.D.	±2.3	±2.4	±2.8	±2.1	±5.9	±2.1	±2.5	±1.9	±1.9	±1.7	
	2.5 mg/kg	N	19	19	19	19	10	10	10	10	10	10	
		Mean	21.4	22.4	21.8	21.3	23.4	25.1*	24.5	24.3	23.8*	21.5**	
		S.D.	±2.9	±3.1	±3.2	±2.1	±2.7	±3.3	±5.7	±4.4	±3.4	±3.3	
	Female	Control	N	20	20	20	20	10	10	10	10	10	10
			Mean	14.1	14.6	14.4	15.5	13.4	13.2	14.0	15.2	13.5	12.2
			S.D.	±2.8	±3.7	±2.9	±2.5	±2.8	±2.3	±2.8	±3.7	±3.0	±3.2
		0.5 mg/kg	N	20	20	20	20	10	10	10	10	10	10
Mean			13.3	15.2	14.0	13.7	13.9	13.8	15.0	14.6	13.8	12.0	
S.D.			±2.5	±2.0	±2.0	±2.9	±1.6	±2.0	±2.3	±1.7	±2.1	±2.6	
2.5 mg/kg		N	20	20	20	20	10	10	10	10	10	10	
		Mean	12.5	15.4	14.3	14.5	14.4	14.2	14.7	15.1	13.5	12.1	
		S.D.	±1.8	±1.9	±2.1	±2.9	±2.0	±1.9	±1.7	±3.0	±2.5	±2.4	
12.5 mg/kg		N	20	20	20	20	10	10	10	10	10	10	
		Mean	13.6	15.5	14.1	14.9	13.8	13.9	16.1	15.4	15.0	12.5	
		S.D.	±2.2	±2.2	±2.5	±2.5	±2.3	±3.2	±2.6	±2.2	±2.4	±2.4	

*: P<0.05, **: P<0.01 (significantly different from control).

Table 4 - continued Food consumption
Male, Female

Sex	Group and dose		Food consumption(g) on day				
			260	288	316	344	364
Male	Control	N	10	10	10	10	10
		Mean	17.4	17.5	18.5	19.4	14.9
		S.D.	±2.0	±3.5	±3.3	±5.0	±3.9
	0.1 mg/kg	N	9	9	9	9	8
		Mean	17.3	16.1	15.9	14.1*	13.8
		S.D.	±3.3	±2.2	±2.6	±4.5	±4.3
	0.5 mg/kg	N	10	10	10	10	10
		Mean	19.9	20.1	19.0	20.5	17.7
		S.D.	±2.8	±2.2	±3.4	±3.6	±2.1
	2.5 mg/kg	N	10	10	10	10	10
		Mean	22.0**	23.1**	21.5	22.5	20.8**
		S.D.	±2.1	±3.3	±3.5	±3.9	±2.5
Female	Control	N	10	10	10	10	10
		Mean	13.3	12.7	12.4	13.9	12.0
		S.D.	±3.5	±3.1	±2.7	±1.8	±1.9
	0.5 mg/kg	N	10	10	10	10	10
		Mean	12.8	13.9	14.7	14.0	13.4
		S.D.	±2.1	±2.5	±1.6	±2.3	±1.1
	2.5 mg/kg	N	10	10	10	10	10
		Mean	13.8	11.5	14.5	15.2	13.2
		S.D.	±2.7	±1.4	±2.1	±2.2	±1.5
	12.5 mg/kg	N	10	10	10	10	9
		Mean	14.8	12.4	14.2	15.2	14.0*
		S.D.	±2.8	±1.8	±2.9	±5.0	±2.0

*: P<0.05, **: P<0.01 (significantly different from control).

Table 5 Urinary findings
Male, Female, 13w

Sex	Group and dose		Urine volume	Osmotic pressure	Specific gravity	Na	K	Cl
			(mL/24hr)	(Osm/kg)		(mEq/24hr)	(mEq/24hr)	(mEq/24hr)
Male	Control	N	10	10	10	10	10	10
		Mean	14.1	1.468	1.050	0.990	2.103	1.302
		S.D.	±8.7	±0.661	±0.022	±0.357	±0.295	±0.380
	0.1 mg/kg	N	10	10	10	10	10	10
		Mean	15.6	1.157	1.040	1.042	2.123	1.444
		S.D.	±5.5	±0.362	±0.012	±0.372	±0.531	±0.440
	0.5 mg/kg	N	10	10	10	10	10	10
		Mean	10.6	1.861	1.062	0.984	2.134	1.320
		S.D.	±2.9	±0.417	±0.014	±0.236	±0.282	±0.198
	2.5 mg/kg	N	9	9	9	9	9	9
		Mean	7.8	2.197**	1.072**	1.147	1.909	1.268
		S.D.	±1.8	±0.382	±0.011	±0.296	±0.372	±0.300
Female	Control	N	10	10	10	10	10	10
		Mean	8.5	1.602	1.051	0.782	1.659	1.143
		S.D.	±5.2	±0.637	±0.019	±0.323	±0.761	±0.470
	0.5 mg/kg	N	10	10	10	10	10	10
		Mean	8.7	1.234	1.040	0.599	1.390	0.878
		S.D.	±2.7	±0.219	±0.008	±0.250	±0.488	±0.345
	2.5 mg/kg	N	10	10	10	10	10	10
		Mean	10.0	1.185	1.039	0.661	1.607	0.973
		S.D.	±3.3	±0.285	±0.009	±0.296	±0.495	±0.285
	12.5 mg/kg	N	10	10	10	10	10	10
		Mean	7.8	1.558	1.051	0.655	1.506	0.952
		S.D.	±2.8	±0.506	±0.016	±0.195	±0.444	±0.305

** : P<0.01 (significantly different from control).

Table 5 - continued

Urinary findings
Male, Female, 13w

Sex	Group and dose	Number of animals	Color		pH							Protein				Glucose
			PY	Y.	5.5	6.0	6.5	7.0	7.5	8.0	8.5	-	±	+	++	-
Male	Control	10	3	7	0	0	0	1	2	6	1	1	5	4	0	10
	0.1 mg/kg	10	3	7	1	0	0	0	0	6	3	1	4	5	0	10
	0.5 mg/kg	10	0	10	0	0	0	0	1	9	0	2	2	5	1	10
	2.5 mg/kg	9	0	9	0	0	0	0	1	5	3	1	4	2	2	9
Female	Control	10	0	10	0	1	1	1	1	5	1	8	0	2	0	10
	0.5 mg/kg	10	0	10	0	0	0	1	1	2	6	10	0	0	0	10
	2.5 mg/kg	10	0	10	0	2	0	0	2	3	3	8	2	0	0	10
	12.5 mg/kg	10	0	10	0	0	0	0	3	5	2	7	3	0	0	10

Not significantly different from control.

Abbreviation: PY, pale yellow; Y, yellow.

Grade sign: -, none; ±, trace; +, slight; ++, moderate; +++, severe; +++++, very severe.

Table 5 - continued
Urinary findings
Male, Female, 13w

Sex	Group and dose	Number of animals	Ketone body		Bilirubin		Occult blood		Urobilinogen (mg/dL)
			-	-	-	+++	-	+++	<1
Male	Control	10	10	10	10	0	10	10	
	0.1 mg/kg	10	10	10	10	0	10	10	
	0.5 mg/kg	10	10	10	10	0	10	10	
	2.5 mg/kg	9	9	9	8	1	9	9	
Female	Control	10	10	10	10	0	10	10	
	0.5 mg/kg	10	10	10	10	0	10	10	
	2.5 mg/kg	10	10	10	10	0	10	10	
	12.5 mg/kg	10	10	10	10	0	10	10	

Not significantly different from control.
Grade sign: -, none; ±, trace; +, slight; ++, moderate; +++, severe.

Table 5 - continued
Urinary findings
Male, Female, 13w

Sex	Group and dose	Number of animals	Urinary sediment											
			Epithelial cells		Erythrocytes		Leukocytes		Casts	Crystals				
			-	-	+	++	+++	-	+	-	+	++	+++	
Male	Control	10	10	10	0	10	0	10	0	10	7	0	2	1
	0.1 mg/kg	10	10	10	0	10	0	10	0	10	9	1	0	0
	0.5 mg/kg	10	10	10	0	9	1	10	0	10	5	2	0	3
	2.5 mg/kg	9	9	8	1	9	0	9	0	9	8	0	1	0
Female	Control	10	10	10	0	10	0	10	0	10	10	0	0	0
	0.5 mg/kg	10	10	10	0	10	0	10	0	10	10	0	0	0
	2.5 mg/kg	10	10	10	0	10	0	10	0	10	10	0	0	0
	12.5 mg/kg	10	10	10	0	10	0	10	0	10	10	0	0	0

Not significantly different from control.

Grade signs are as follows.

Epithelial cells: -, < 3/field; +, 3/field \leq and < 10/field; ++, 10/field \leq and < 20/field; +++, \geq 20/field.
 Erythrocytes : -, < 10/field; +, 10/field \leq and < 30/field; ++, 30/field \leq and < 100/field; +++, countless.
 Leukocytes : -, < 3/field; +, 3/field \leq and < 20/field; ++, 20/field \leq and < 40/field; +++, \geq 40/field.
 Casts : -, none; +, \geq 1/all field.
 Crystals : -, < 10/field; +, 10/field \leq and < 20/field; ++, 20/field \leq and < 30/field; +++, countless.

Table 6 Urinary findings
Male, Female, 52w

Sex	Group and dose		Urine volume (mL/24hr)	Osmotic pressure (Osm/kg)	Specific gravity	Na (mEq/24hr)	K (mEq/24hr)	Cl (mEq/24hr)
Male	Control	N	10	10	10	10	10	10
		Mean	9.3	1.316	1.047	0.663	1.501	0.774
		S. D.	±3.3	±0.305	±0.013	±0.468	±0.480	±0.522
	0.1 mg/kg	N	8	8	8	8	8	8
		Mean	7.9	1.556	1.056	0.546	1.376	0.566
		S. D.	±3.0	±0.330	±0.013	±0.299	±0.270	±0.306
	0.5 mg/kg	N	10	10	10	10	10	10
		Mean	9.1	1.910**	1.065*	0.822	1.801	0.911
		S. D.	±2.5	±0.418	±0.016	±0.373	±0.286	±0.394
	2.5 mg/kg	N	10	10	10	10	10	10
		Mean	8.6	1.809*	1.061	0.870	1.517	0.831
		S. D.	±2.2	±0.417	±0.013	±0.461	±0.413	±0.353
Female	Control	N	10	10	10	10	10	10
		Mean	9.9	1.325	1.046	0.727	1.836	1.043
		S. D.	±5.0	±0.352	±0.013	±0.425	±0.648	±0.505
	0.5 mg/kg	N	10	10	10	10	10	10
		Mean	12.6	1.200	1.042	0.730	1.753	1.019
		S. D.	±7.3	±0.509	±0.017	±0.251	±0.226	±0.263
	2.5 mg/kg	N	10	10	10	10	10	10
		Mean	14.7	1.043	1.037	0.722	1.780	1.077
		S. D.	±8.7	±0.432	±0.018	±0.309	±0.393	±0.346
	12.5 mg/kg	N	9	9	9	9	9	9
		Mean	19.0*	0.840*	1.030	0.999	2.167	1.315
		S. D.	±9.0	±0.219	±0.008	±0.256	±0.418	±0.308

*: P<0.05, **: P<0.01 (significantly different from control).

Table 6 - continued

Urinary findings
Male, Female, 52w

Sex	Group and dose	Number of animals	Color		pH							Protein						Glucose
			PY	Y	5.5	6.0	6.5	7.0	7.5	8.0	8.5	-	±	+	++	+++	++++	-
Male	Control	10	2	8	1	0	0	1	3	4	1	2	0	3	5	0	0	10
	0.1 mg/kg	8	0	8	0	0	0	1	1	6	0	0	2	5	1	0	0	8
	0.5 mg/kg	10	0	10	2	2	3	0	1	2	0	0	1	3	3	2	1	10
	2.5 mg/kg	10	0	10	0	2	0	1	1	4	2	0	1	5	3	1	0	10
Female	Control	10	0	10	2	0	0	0	1	3	4	6	2	2	0	0	0	10
	0.5 mg/kg	10	1	9	1	1	1	1	1	4	1	6	1	3	0	0	0	10
	2.5 mg/kg	10	3	7	2	0	3	1	1	2	1	5	1	3	1	0	0	10
	12.5 mg/kg	9	2	7	1	1	3	1	1	2	0	3	4	2	0	0	0	9

Not significantly different from control.

Abbreviation: PY, pale yellow; Y, yellow; YB, yellowish brown; B, brown.

Grade sign: -, none; ±, trace; +, slight; ++, moderate; +++, severe; +++++, very severe.

Table 6 - continued

Urinary findings
Male, Female, 52w

Sex	Group and dose	Number of animals	Ketone body	Bilirubin	Occult blood			Urobilinogen (mg/dL)
			-	-	-	++	+++	<1
Male	Control	10	10	10	9	1	0	10
	0.1 mg/kg	8	8	8	7	0	1	8
	0.5 mg/kg	10	10	10	9	0	1	10
	2.5 mg/kg	10	10	10	10	0	0	10
Female	Control	10	10	10	10	0	0	10
	0.5 mg/kg	10	10	10	10	0	0	10
	2.5 mg/kg	10	10	10	10	0	0	10
	12.5 mg/kg	9	9	9	9	0	0	9

Not significantly different from control.

Grade sign: -, none; ±, trace; +, slight; ++, moderate; +++, severe; +++++, very severe.

Table 6 - continued

Urinary findings
Male, Female, 52w

Sex	Group and dose	Number of animals	Urinary sediment									
			Epithelial cells		Erythrocytes		Leukocytes		Casts	Crystals		
			-	+	-	+	-	+	-	-	+	+++
Male	Control	10	10		10	0	9	1	10	10	0	0
	0.1 mg/kg	8	8		8	0	7	1	8	7	0	1
	0.5 mg/kg	10	10		9	1	9	1	10	9	1	0
	2.5 mg/kg	10	10		10	0	10	0	10	9	1	0
Female	Control	10	10		10	0	10	0	10	9	1	0
	0.5 mg/kg	10	10		10	0	10	0	10	8	2	0
	2.5 mg/kg	10	10		10	0	10	0	10	10	0	0
	12.5 mg/kg	9	9		9	0	9	0	9	9	0	0

Not significantly different from control.

Grade signs are as follows.

Epithelial cells: -, < 3/field; +, 3/field \leq and < 10/field; ++, 10/field \leq and < 20/field; +++, \geq 20/field.
 Erythrocytes : -, < 10/field; +, 10/field \leq and < 30/field; ++, 30/field \leq and < 100/field; +++, countless.
 Leukocytes : -, < 3/field; +, 3/field \leq and < 20/field; ++, 20/field \leq and < 40/field; +++, \geq 40/field.
 Casts : -, none; +, \geq 1/all field.
 Crystals : -, < 10/field; +, 10/field \leq and < 20/field; ++, 20/field \leq and < 30/field; +++, countless.

Table 7 Hematological findings
Male, Female, 13w

Sex	Group and dose		Leukocytes ($10^3 / \mu\text{L}$)	Erythrocytes ($10^4 / \mu\text{L}$)	Hemoglobin (g/dL)	Hematocrit (%)	MCV (fL)	MCH (pg)	MCHC (g/dL)	Reticulocyte ($10^4 / \mu\text{L}$)	Platelets ($10^4 / \mu\text{L}$)
Male	Control	N	10	10	10	10	10	10	10	10	10
		Mean	7.83	855	15.6	43.3	50.6	18.3	36.1	15.8	103.4
		S.D.	± 1.32	± 27	± 0.4	± 1.6	± 1.6	± 0.5	± 0.7	± 2.8	± 11.2
	0.1 mg/kg	N	10	10	10	10	10	10	10	10	10
		Mean	8.63	870	15.5	43.2	49.6	17.8	35.9	16.3	108.7
		S.D.	± 2.72	± 29	± 0.5	± 1.2	± 1.1	± 0.5	± 0.4	± 1.8	± 8.2
	0.5 mg/kg	N	10	10	10	10	10	10	10	10	10
		Mean	9.08	828	15.0*	41.6*	50.3	18.1	36.0	16.2	112.9
		S.D.	± 2.48	± 43	± 0.6	± 1.8	± 0.9	± 0.5	± 0.7	± 3.2	± 16.0
	2.5 mg/kg	N	9	9	9	9	9	9	9	9	9
		Mean	9.97	807**	14.3**	40.0**	49.6	17.7	35.7	14.8	130.5*
		S.D.	± 1.88	± 22	± 0.6	± 1.3	± 2.6	± 1.0	± 0.5	± 3.6	± 27.1
Female	Control	N	10	10	10	10	10	10	10	10	10
		Mean	4.94	768	13.9	40.1	52.2	18.1	34.6	16.5	106.1
		S.D.	± 1.16	± 38	± 0.5	± 1.7	± 1.1	± 0.4	± 0.5	± 3.4	± 12.1
	0.5 mg/kg	N	10	10	10	10	10	10	10	10	10
		Mean	4.30	793	14.1	40.7	51.3	17.7	34.6	13.9	110.4
		S.D.	± 1.04	± 40	± 0.6	± 2.2	± 0.7	± 0.4	± 0.6	± 1.9	± 6.8
	2.5 mg/kg	N	10	10	10	10	10	10	10	10	10
		Mean	4.95	762	13.8	39.5	51.9	18.1	35.0	14.8	117.4
		S.D.	± 0.99	± 23	± 0.4	± 0.9	± 1.3	± 0.5	± 0.3	± 3.4	± 11.6
	12.5 mg/kg	N	10	10	10	10	10	10	10	10	10
		Mean	5.18	753	13.4	38.1*	50.6**	17.7	35.1*	13.7	106.2
		S.D.	± 1.70	± 25	± 0.5	± 1.2	± 1.0	± 0.5	± 0.5	± 1.6	± 9.9

*: $P < 0.05$, **: $P < 0.01$ (significantly different from control).

Table 7 - continued
Hematological findings
Male, Female, 13w

Sex	Group and dose		PT (sec)	APTT (sec)
Male	Control	N	10	10
		Mean	15.2	24.6
		S.D.	±2.7	±1.9
	0.1 mg/kg	N	10	10
		Mean	14.9	24.1
		S.D.	±1.1	±1.9
	0.5 mg/kg	N	10	10
		Mean	15.1	23.0
		S.D.	±1.5	±1.5
	2.5 mg/kg	N	9	9
		Mean	14.3	23.5
		S.D.	±1.4	±3.1
Female	Control	N	10	10
		Mean	11.7	19.2
		S.D.	±0.5	±1.5
	0.5 mg/kg	N	10	10
		Mean	11.7	19.7
		S.D.	±0.3	±0.9
	2.5 mg/kg	N	10	10
		Mean	11.7	19.0
		S.D.	±0.3	±1.6
	12.5 mg/kg	N	10	10
		Mean	11.8	19.2
		S.D.	±0.4	±1.5

Not significantly different from control.

Table 7 - continued
Hematological findings
Male, Female, 13w

Sex	Group and dose		Differential leukocyte count					
			Eosinophils	Neutrophils	Lymphocytes	Basophils	Monocytes	Large unstained cells
			(10 ² / μ L)	(10 ² / μ L)	(10 ² / μ L)	(10 ² / μ L)	(10 ² / μ L)	(10 ² / μ L)
Male	Control	N	10	10	10	10	10	10
		Mean	1.2	16.2	58.7	0.1	1.7	0.3
		S. D.	± 0.6	± 6.1	± 14.3	± 0.1	± 0.5	± 0.1
	0.1 mg/kg	N	10	10	10	10	10	10
		Mean	1.4	16.8	65.5	0.2	1.8	0.5
		S. D.	± 0.4	± 9.8	± 23.5	± 0.1	± 0.7	± 0.4
	0.5 mg/kg	N	10	10	10	10	10	10
		Mean	1.3	13.8	72.9	0.2	2.0	0.7*
		S. D.	± 0.7	± 5.1	± 21.7	± 0.1	± 1.0	± 0.3
	2.5 mg/kg	N	9	9	9	9	9	9
		Mean	1.1	14.4	81.1	0.2	2.2	0.7
		S. D.	± 0.4	± 5.5	± 19.9	± 0.1	± 0.7	± 0.5
Female	Control	N	10	10	10	10	10	10
		Mean	0.9	7.1	40.1	0.1	0.8	0.4
		S. D.	± 0.4	± 2.7	± 9.5	± 0.1	± 0.3	± 0.2
	0.5 mg/kg	N	10	10	10	10	10	10
		Mean	0.8	6.3	34.9	0.1	0.7	0.3
		S. D.	± 0.5	± 1.6	± 8.5	± 0.1	± 0.3	± 0.1
	2.5 mg/kg	N	10	10	10	10	10	10
		Mean	0.8	8.3	39.4	0.1	0.6	0.4
		S. D.	± 0.3	± 3.8	± 8.7	± 0.0	± 0.2	± 0.2
	12.5 mg/kg	N	10	10	10	10	10	10
		Mean	0.9	6.2	43.5	0.1	0.8	0.3
		S. D.	± 0.3	± 2.2	± 15.2	± 0.1	± 0.4	± 0.2

*: P<0.05 (significantly different from control).

Table 8 Hematological findings
Male, Female, 52w

Sex	Group and dose		Leukocytes	Erythrocytes	Hemoglobin	Hematocrit	MCV	MCH	MCHC	Reticulocyte	Platelets
			($10^3 / \mu\text{L}$)	($10^4 / \mu\text{L}$)	(g/dL)	(%)	(fL)	(pg)	(g/dL)	($10^4 / \mu\text{L}$)	($10^4 / \mu\text{L}$)
Male	Control	N	10	10	10	10	10	10	10	10	10
		Mean	7.98	840	14.0	44.2	52.7	16.7	31.7	18.2	106.5
		S. D.	± 1.24	± 68	± 1.1	± 2.9	± 2.1	± 0.8	± 0.8	± 8.4	± 12.6
	0.1 mg/kg	N	8	8	8	8	8	8	8	8	8
		Mean	8.22	780	13.1	41.3	53.1	16.7	31.5	20.1	110.2
		S. D.	± 3.46	± 145	± 2.7	± 7.4	± 1.2	± 0.7	± 1.5	± 9.8	± 28.5
	0.5 mg/kg	N	10	10	10	10	10	10	10	10	10
		Mean	6.69	754*	12.7	40.3	53.9	16.9	31.3	27.1	123.7
		S. D.	± 0.98	± 133	± 2.1	± 5.7	± 4.5	± 1.0	± 1.1	± 20.4	± 28.5
	2.5 mg/kg	N	10	10	10	10	10	10	10	10	10
		Mean	7.90	778*	12.9	40.7*	52.3	16.6	31.8	15.7	140.1**
		S. D.	± 2.19	± 66	± 1.1	± 3.6	± 2.3	± 0.7	± 0.3	± 3.3	± 13.6
Female	Control	N	10	10	10	10	10	10	10	10	10
		Mean	3.83	707	13.2	40.3	57.5	18.8	32.7	14.9	90.2
		S. D.	± 1.30	± 100	± 1.4	± 3.8	± 4.3	± 1.0	± 0.9	± 8.9	± 10.0
	0.5 mg/kg	N	10	10	10	10	10	10	10	10	10
		Mean	3.73	708	13.5	41.0	58.1	19.1	33.0	16.4	94.2
		S. D.	± 0.96	± 62	± 0.8	± 2.5	± 2.3	± 0.7	± 0.5	± 9.6	± 14.7
	2.5 mg/kg	N	10	10	10	10	10	10	10	10	10
		Mean	3.98	730	13.5	41.3	56.6	18.5	32.7	13.9	101.5
		S. D.	± 1.44	± 55	± 1.0	± 3.0	± 2.4	± 0.8	± 0.6	± 5.8	± 13.9
	12.5 mg/kg	N	9	9	9	9	9	9	9	9	9
		Mean	3.69	673	12.3	37.3	56.1	18.4	32.9	17.1	105.6*
		S. D.	± 0.58	± 115	± 1.5	± 4.4	± 4.8	± 1.4	± 0.4	± 15.1	± 11.9

*: $P < 0.05$, **: $P < 0.01$ (significantly different from control).

Table 8 - continued
Hematological findings
Male, Female, 52w

Sex	Group and dose		PT (sec)	APTT (sec)
Male	Control	N	10	10
		Mean	13.5	21.5
		S.D.	±1.0	±1.5
	0.1 mg/kg	N	8	8
		Mean	13.8	20.9
		S.D.	±1.0	±2.7
	0.5 mg/kg	N	10	10
		Mean	14.5	21.2
		S.D.	±1.9	±2.6
	2.5 mg/kg	N	10	10
		Mean	21.8**	29.5
		S.D.	±9.0	±9.3
Female	Control	N	10	10
		Mean	12.3	18.4
		S.D.	±0.8	±0.9
	0.5 mg/kg	N	10	10
		Mean	12.9	18.5
		S.D.	±0.7	±0.9
	2.5 mg/kg	N	10	10
		Mean	12.5	17.7
		S.D.	±0.5	±1.4
	12.5 mg/kg	N	9	9
		Mean	12.1	17.7
		S.D.	±0.5	±1.2

**; P<0.01 (significantly different from control).

Table 8 - continued
Hematological findings
Male, Female, 52w

Sex	Group and dose		Differential leukocyte count					
			Eosinophils	Neutrophils	Lymphocytes	Basophils	Monocytes	Large unstained cells
			(10 ² / μ L)	(10 ² / μ L)	(10 ² / μ L)	(10 ² / μ L)	(10 ² / μ L)	(10 ² / μ L)
Male	Control	N	10	10	10	10	10	10
		Mean	1.2	26.2	47.8	0.1	3.0	1.5
		S.D.	± 0.3	± 9.9	± 11.9	± 0.0	± 0.9	± 2.0
	0.1 mg/kg	N	8	8	8	8	8	8
		Mean	1.0	30.8	46.4	0.1	2.5	1.5
		S.D.	± 0.6	± 29.1	± 6.5	± 0.1	± 0.5	± 2.4
	0.5 mg/kg	N	10	10	10	10	10	10
		Mean	0.9	18.6	44.3	0.1	2.3	0.7
		S.D.	± 0.3	± 7.3	± 6.3	± 0.0	± 0.7	± 0.2
	2.5 mg/kg	N	10	10	10	10	10	10
		Mean	1.1	17.6	56.2	0.1	2.9	1.1
		S.D.	± 0.5	± 7.5	± 17.5	± 0.1	± 0.8	± 0.7
Female	Control	N	10	10	10	10	10	10
		Mean	0.6	10.1	25.4	0.0	1.4	0.7
		S.D.	± 0.2	± 8.0	± 8.2	± 0.0	± 0.8	± 0.3
	0.5 mg/kg	N	10	10	10	10	10	10
		Mean	0.7	11.0	23.3	0.0	1.6	0.6
		S.D.	± 0.2	± 4.0	± 7.2	± 0.0	± 0.5	± 0.3
	2.5 mg/kg	N	10	10	10	10	10	10
		Mean	0.9	12.1	24.6	0.0	1.6	0.6
		S.D.	± 0.4	± 6.7	± 8.2	± 0.0	± 0.6	± 0.3
	12.5 mg/kg	N	9	9	9	9	9	9
		Mean	0.8	9.2	24.8	0.0	1.6	0.5
		S.D.	± 0.2	± 1.9	± 6.3	± 0.0	± 0.5	± 0.2

Not significantly different from control.

Table 9 Biochemical findings
Male, Female, 13w

Sex	Group and dose		T.Protein (g/dL)	A/G ratio	α_1 -Globulin (%)	α_2 -Globulin (%)	β -Globulin (%)	γ -Globulin (%)	Albumin (%)
Male	Control	N	10	10	10	10	10	10	10
		Mean	5.8	1.22	18.7	7.1	15.2	4.2	54.8
		S.D.	±0.3	±0.12	±1.6	±0.7	±0.8	±0.5	±2.3
	0.1 mg/kg	N	10	10	10	10	10	10	10
		Mean	5.8	1.30	17.9	6.8	14.4	4.3	56.6
		S.D.	±0.2	±0.09	±1.6	±0.6	±0.6	±0.6	±1.6
	0.5 mg/kg	N	10	10	10	10	10	10	10
		Mean	5.7	1.67**	15.6**	5.9**	11.5**	4.6	62.4**
		S.D.	±0.5	±0.23	±1.3	±0.6	±1.0	±0.8	±2.9
	2.5 mg/kg	N	9	9	9	9	9	9	9
		Mean	5.8	2.09**	12.1**	5.6**	9.9**	5.0	67.4**
		S.D.	±0.5	±0.27	±2.4	±0.6	±0.7	±1.4	±3.0
Female	Control	N	10	10	10	10	10	10	10
		Mean	6.2	1.78	13.8	5.6	12.6	3.9	64.0
		S.D.	±0.4	±0.16	±1.0	±0.8	±0.9	±0.8	±2.0
	0.5 mg/kg	N	10	10	10	10	10	10	10
		Mean	6.3	1.87	12.9	5.6	12.4	4.3	64.9
		S.D.	±0.2	±0.22	±1.7	±0.2	±1.2	±1.0	±2.8
	2.5 mg/kg	N	10	10	10	10	10	10	10
		Mean	6.4	1.93	12.6	5.5	12.1	4.2	65.7
		S.D.	±0.4	±0.19	±1.6	±0.6	±1.4	±1.0	±2.2
	12.5 mg/kg	N	10	10	10	10	10	10	10
		Mean	6.7*	2.24**	12.9	4.7*	9.9**	3.6	68.9**
		S.D.	±0.5	±0.31	±1.8	±0.5	±0.8	±1.1	±2.9

*: P<0.05, **: P<0.01 (significantly different from control).

Table 9 - continued
Biochemical findings
Male, Female, 13w

Sex	Group and dose		T.Bilirubin (mg/dL)	AST (IU/L)	ALT (IU/L)	ALP (IU/L)	T.Cholesterol (mg/dL)	Triglycerides (mg/dL)	Phospholipids (mg/dL)	Glucose (mg/dL)
Male	Control	N	10	10	10	10	10	10	10	10
		Mean	0.0	90	35	164	68	48	119	121
		S. D.	±0.0	±22	±29	±23	±12	±21	±21	±9
	0.1 mg/kg	N	10	10	10	10	10	10	10	10
		Mean	0.0	118	47	216	64	43	116	120
		S. D.	±0.0	±66	±58	±57	±12	±12	±23	±7
	0.5 mg/kg	N	10	10	10	10	10	10	10	10
		Mean	0.0	83	23	373**	59	58	125	154**
		S. D.	±0.0	±14	±4	±60	±13	±29	±27	±13
	2.5 mg/kg	N	9	9	9	9	9	9	9	9
		Mean	0.0	94	32	619**	58	65	131	151**
		S. D.	±0.0	±16	±9	±115	±9	±19	±16	±9
Female	Control	N	10	10	10	10	10	10	10	10
		Mean	0.1	75	20	92	75	29	150	119
		S. D.	±0.1	±20	±7	±30	±12	±20	±21	±13
	0.5 mg/kg	N	10	10	10	10	10	10	10	10
		Mean	0.0*	69	18	107	78	24	155	117
		S. D.	±0.0	±8	±6	±25	±10	±9	±15	±10
	2.5 mg/kg	N	10	10	10	10	10	10	10	10
		Mean	0.0	77	17	101	72	23	147	118
		S. D.	±0.0	±14	±2	±31	±12	±10	±23	±15
	12.5 mg/kg	N	10	10	10	10	10	10	10	10
		Mean	0.0*	68	18	136	83	35	169	130
		S. D.	±0.0	±10	±2	±81	±7	±13	±16	±10

*: P<0.05, **: P<0.01 (significantly different from control).